Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer

Purpose: The cancer/germline antigen NY-ESO-1 is variably expressed in epithelial ovarian cancer (EOC), with most tumors showing low or heterogeneous expression, which limits patient responses to NY-ESO-1 vaccine therapy. We tested the hypothesis that promoter and global genomic DNA methylation status correlates with intertumor and intratumor NY-ESO-1 expression status in EOC. Experimental Design: We utilized 78 EOC tumors and 10 normal ovary controls for quantitative DNA methylation analyses and NY-ESO-1 expression analysis by immunohistochemistry (IHC) and quantitative reverse transcriptase PCR. A subset of EOC tumors were used to perform microdissections of NY-ESO-1 IHC-positive and NY-ESO-1 IHC-negative tissue regions, followed by DNA methylation analyses. EOC cell lines were treated in vitro with decitabine to determine the functional contribution of DNA methylation to NY-ESO-1 gene regulation in EOC. Results: Compared with normal ovary, bulk EOC tissues display increased NY-ESO-1 expression, reduced NY-ESO-1 promoter methylation, and reduced LINE-1 DNA methylation. However, NY-ESO-1 expression is not significantly associated with NY-ESO-1 promoter methylation status in bulk tumors. We hypothesized that this resulted from heterogeneous intratumor NY-ESO-1 expression. Supporting this idea, experiments using microdissected material revealed that intertumor and intratumor NY-ESO-1 expression heterogeneity is significantly correlated with promoter and global DNA methylation status in EOC. Moreover, decitabine treatment functionally restored NY-ESO-1 expression in nonexpressing EOC cell lines. Conclusion: DNA methylation status is associated with both intertumor and intratumor NY-ESO-1 expression status in EOC. These findings support a novel chemoimmunotherapy approach using decitabine to augment NY-ESO-1 vaccine therapy for treatment of recurrent EOC.

[1]  F. Brasseur,et al.  Expression of BORIS in melanoma: Lack of association with MAGE‐A1 activation , 2008, International journal of cancer.

[2]  P. Helmbold,et al.  Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. , 2007, Histology and histopathology.

[3]  M. L. Beau,et al.  Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins , 2007, Oncogene.

[4]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[5]  D. Schrump,et al.  Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells , 2007, Oncogene.

[6]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[7]  Petra A. Link,et al.  Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b , 2006, Oncogene.

[8]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[9]  A. Karpf.  A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy , 2006, Epigenetics.

[10]  K. Pantel,et al.  Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells , 2006, Molecular Cancer Research.

[11]  T. Boon,et al.  Transient Down-regulation of DNMT1 Methyltransferase Leads to Activation and Stable Hypomethylation of MAGE-A1 in Melanoma Cells* , 2006, Journal of Biological Chemistry.

[12]  Victor V Lobanenkov,et al.  Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. , 2005, Cancer research.

[13]  Victor V Lobanenkov,et al.  Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. , 2005, Cancer research.

[14]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[15]  Liguo Song,et al.  Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. , 2005, Analytical chemistry.

[16]  M. Maio,et al.  Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.

[17]  Peter W. Laird,et al.  DNA Hypomethylation and Ovarian Cancer Biology , 2004, Cancer Research.

[18]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[19]  M. Maio,et al.  Epigenetic targets for immune intervention in human malignancies , 2003, Oncogene.

[20]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[21]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[22]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[23]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[24]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[25]  Thierry Boon,et al.  DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter , 1999, Molecular and Cellular Biology.

[26]  P. Jones,et al.  The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. , 1998, Cancer research.

[27]  O. de Backer,et al.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[29]  K. Odunsi,et al.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. , 2007, Cancer immunity.

[30]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[31]  S. Courtois,et al.  Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene , 2004, Immunogenetics.

[32]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[33]  D. Schrump,et al.  NY-ESO-1 may be a potential target for lung cancer immunotherapy. , 1999, The cancer journal from Scientific American.